| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 850% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 450% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 800% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 250% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1900% | Northcoast Research | → $40 | Initiates Coverage On | → Outperform |
| 09/10/2018 | 1050% | Laidlaw & Co. | → $23 | Initiates Coverage On | → Buy |
| 09/10/2018 | 1150% | Cantor Fitzgerald | → $25 | Initiates Coverage On | → Overweight |
Aridis Pharmaceuticals Questions & Answers
The latest price target for Aridis Pharmaceuticals (NASDAQ: ARDS) was reported by Maxim Group on August 16, 2022. The analyst firm set a price target for $0.00 expecting ARDS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Aridis Pharmaceuticals (NASDAQ: ARDS) was provided by Maxim Group, and Aridis Pharmaceuticals downgraded their hold rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on August 16, 2022 so you should expect the next rating to be made available sometime around August 16, 2023.
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $2.00, which is out of the analyst's predicted range.